{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-286158","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.951672+00:00","generated_at":"2026-05-16T18:48:02.724102+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cogent completes $230M 1.625% convertible senior notes offering due 2031","bullets":["Aggregate principal $230M including full exercise of $30M over-allotment option by underwriters.","Notes bear 1.625% interest payable semiannually on May 15 and Nov 15, starting May 15, 2026; mature Nov 15, 2031.","Initial conversion rate 22.2469 shares per $1,000 principal (conversion price ~$44.95); settlement in cash, stock, or combo at company's election.","Notes are senior unsecured obligations; redeemable at company's option after Nov 20, 2029 subject to stock price conditions.","Noteholders may require repurchase upon a Fundamental Change (e.g., business combination, delisting) at principal plus accrued interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-286158","json":"https://secwatch.observer/filing/0001193125-25-286158.json","markdown":"https://secwatch.observer/filing/0001193125-25-286158.md","text":"https://secwatch.observer/filing/0001193125-25-286158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525286158/0001193125-25-286158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525286158/d888858d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:48:02.724102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"349708f443cc74812353fbb9c0d9bc28c37c6f93","claim":"Cogent Biosciences, Inc. incurred convertible notes of $230,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 1.625% per year maturing November 15, 2031.","evidence_excerpt":"On November 18, 2025, Cogent Biosciences, Inc. (the “Company”) completed its previously-announced public offering (the “Offering”) of $230,000,000 aggregate principal amount of its 1.625% Convertible Senior Notes due 2031","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525286158/0001193125-25-286158-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$230,000,000 aggregate principal amount"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Rate","value":"1.625% per year"},{"label":"Maturity","value":"November 15, 2031"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}